Systematic review of safety in paediatric drug trials published in 2007

Background: There is now greater involvement of children in drug trials to ensure that paediatric medicines are supported by sound scientific evidence. The safety of the participating children is of paramount importance. Previous research shows that these children can suffer moderate and severe adve...

Full description

Bibliographic Details
Main Authors: Nor Aripin, Khairun Nain Bin, Choonara, Imti, Sammons, Helen
Format: Article
Published: Springer Verlag 2012
Subjects:
Online Access:https://eprints.nottingham.ac.uk/2579/
_version_ 1848790821686476800
author Nor Aripin, Khairun Nain Bin
Choonara, Imti
Sammons, Helen
author_facet Nor Aripin, Khairun Nain Bin
Choonara, Imti
Sammons, Helen
author_sort Nor Aripin, Khairun Nain Bin
building Nottingham Research Data Repository
collection Online Access
description Background: There is now greater involvement of children in drug trials to ensure that paediatric medicines are supported by sound scientific evidence. The safety of the participating children is of paramount importance. Previous research shows that these children can suffer moderate and severe adverse drug reactions (ADRs) in clinical trials, yet very few of the trials designated a data safety monitoring board (DSMB) to oversee the trial. Methods: Safety data from a systematic review of paediatric drug randomised controlled trials (RCTs) published in 2007 were analysed. All reported adverse events (AEs) were classified and assessed to determine whether an ADR had been experienced. ADRs were then categorised according to severity. Each trial report was examined as to whether an independent DSMB was in place. Results: Of the 582 paediatric drug RCTs analysed, 210 (36%) reported that a serious AE had occurred, and in 15% mortality was reported. ADRs were detected in more than half of the RCTs (305); 66 (11%) were severe, and 79 (14%) were moderate. Severe ADRs involved a wide range of organ systems and were frequently associated with cytotoxic drugs, antiparasitics, anticonvulsants and psychotropic drugs. Two RCTs reported significantly higher mortality rates in the treatment group. Only 69 (12%) of the RCTs stated there was a DSMB. DSMBs terminated five RCTs and changed the protocol in one. Conclusions: Children participating in drug RCTs experience a significant amount and a wide range of ADRs. DSMBs are needed to ensure the safety of paediatric participants in clinical drug trials
first_indexed 2025-11-14T18:18:43Z
format Article
id nottingham-2579
institution University of Nottingham Malaysia Campus
institution_category Local University
last_indexed 2025-11-14T18:18:43Z
publishDate 2012
publisher Springer Verlag
recordtype eprints
repository_type Digital Repository
spelling nottingham-25792020-05-04T20:21:53Z https://eprints.nottingham.ac.uk/2579/ Systematic review of safety in paediatric drug trials published in 2007 Nor Aripin, Khairun Nain Bin Choonara, Imti Sammons, Helen Background: There is now greater involvement of children in drug trials to ensure that paediatric medicines are supported by sound scientific evidence. The safety of the participating children is of paramount importance. Previous research shows that these children can suffer moderate and severe adverse drug reactions (ADRs) in clinical trials, yet very few of the trials designated a data safety monitoring board (DSMB) to oversee the trial. Methods: Safety data from a systematic review of paediatric drug randomised controlled trials (RCTs) published in 2007 were analysed. All reported adverse events (AEs) were classified and assessed to determine whether an ADR had been experienced. ADRs were then categorised according to severity. Each trial report was examined as to whether an independent DSMB was in place. Results: Of the 582 paediatric drug RCTs analysed, 210 (36%) reported that a serious AE had occurred, and in 15% mortality was reported. ADRs were detected in more than half of the RCTs (305); 66 (11%) were severe, and 79 (14%) were moderate. Severe ADRs involved a wide range of organ systems and were frequently associated with cytotoxic drugs, antiparasitics, anticonvulsants and psychotropic drugs. Two RCTs reported significantly higher mortality rates in the treatment group. Only 69 (12%) of the RCTs stated there was a DSMB. DSMBs terminated five RCTs and changed the protocol in one. Conclusions: Children participating in drug RCTs experience a significant amount and a wide range of ADRs. DSMBs are needed to ensure the safety of paediatric participants in clinical drug trials Springer Verlag 2012-02 Article PeerReviewed Nor Aripin, Khairun Nain Bin, Choonara, Imti and Sammons, Helen (2012) Systematic review of safety in paediatric drug trials published in 2007. European Journal of Clinical Pharmacology, 68 (2). pp. 189-194. ISSN 0031-6970 Paediatric clinical trials Adverse drug reactions Drug safety Data safety monitoring boards Systematic review http://link.springer.com/article/10.1007%2Fs00228-011-1112-6 doi:10.1007/s00228-011-1112-6 doi:10.1007/s00228-011-1112-6
spellingShingle Paediatric clinical trials
Adverse drug reactions
Drug safety
Data safety monitoring boards
Systematic review
Nor Aripin, Khairun Nain Bin
Choonara, Imti
Sammons, Helen
Systematic review of safety in paediatric drug trials published in 2007
title Systematic review of safety in paediatric drug trials published in 2007
title_full Systematic review of safety in paediatric drug trials published in 2007
title_fullStr Systematic review of safety in paediatric drug trials published in 2007
title_full_unstemmed Systematic review of safety in paediatric drug trials published in 2007
title_short Systematic review of safety in paediatric drug trials published in 2007
title_sort systematic review of safety in paediatric drug trials published in 2007
topic Paediatric clinical trials
Adverse drug reactions
Drug safety
Data safety monitoring boards
Systematic review
url https://eprints.nottingham.ac.uk/2579/
https://eprints.nottingham.ac.uk/2579/
https://eprints.nottingham.ac.uk/2579/